Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis
| Autor: | Guozi Chen, Youhong Long, Weihua Wang, Qinxiang Tan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Sorafenib
Cancer Research medicine.medical_specialty Sunitinib business.industry Therapeutic effect Hazard ratio Articles General Medicine Pharmacology medicine.disease Gastroenterology Axitinib Pazopanib Immunology and Microbiology (miscellaneous) Internal medicine medicine business Adverse effect Progressive disease medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. 9:2275-2280 |
| ISSN: | 1792-1015 1792-0981 |
| DOI: | 10.3892/etm.2015.2427 |
| Popis: | This study aimed to compare the therapeutic effects and adverse events of the multikinase inhibitors sorafenib, sunitinib, pazopanib and axitinib in advanced renal cell carcinoma (RCC). A meta-analysis of randomized controlled trials was performed to assess the effects of multikinase inhibitors among patients with advanced RCC. The data of median progression-free survival (PFS), median overall survival (OS), progressive disease rate (PDR), objective response rate (ORR) and grade 3/4 adverse events were extracted to assess therapeutic effects and toxicity, respectively. It was found that multikinase inhibitors are more effective in extending PFS [hazard ratio (HR)=0.58; 95% confidence interval (CI): 0.45–0.74; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|